Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Scientific Reports|June 29, 2023
Evaluation of the cardiac subvolume dose and myocardial perfusion in left breast cancer patients with postoperative radiotherapy: a prospective studyShan-Ying Wang, Kuan-Heng Lin, Yen-Wen Wu, et al.European Radiology|December 14, 2016
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinomaBang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, et al.Radiology|May 13, 2016
Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic TherapyBang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, et al.European Radiology|May 18, 2018
Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancerBang-Bin Chen, Yen-Shen Lu, Chih-Wei Yu, et al.Thoracic Cancer|August 9, 2023
Integrating subvolume dose and myocardial perfusion imaging parameters to assess the impact of radiation therapy on heart function in breast cancer patients: A comparative analysis between left- and right-sided breast cancerShan-Ying Wang, Wei-Ta Tsai, Kuan-Heng Lin, et al.Radiology|January 8, 2011
Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remissionBang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, et al.European Journal of Radiology|October 20, 2019
Prognostic value of <sup>18</sup>F-FDG PET/MR imaging biomarkers in oesophageal squamous cell carcinomaChih-Wei Yu, Xin-Jia Chen, Yen-Heng Lin, et al.Journal of Hepatology|February 23, 2011
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracilChao-Yu Hsu, Ying-Chun Shen, Chih-Wei Yu, et al.Journal of Hepatology|January 17, 2012
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled studyChiun Hsu, Tsai-Sheng Yang, Teh-Ia Huo, et al.BMC Cancer|July 15, 2016
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancerBang-Bin Chen, Yen-Shen Lu, Ching-Hung Lin, et al.Pageof 3